Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Zhi Liu

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
Nature Communications|February 5, 2023
Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significanceMei Lin, Xiao-Long Zhang, Rui You, et al.
Cancer Cell|January 19, 2024
Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinomaXiao-Jing Du, Gao-Yuan Wang, Xiao-Dong Zhu, et al.
Lancet (London, England)|February 26, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialRui You, You-Ping Liu, Yu-Long Xie, et al.
Nature|March 12, 2026
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinomaJiawei Lv, Dan-Xue Zheng, Jin-Hui Liang, et al.
JAMA Oncology|October 10, 2024
Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging ClassificationJian-Ji Pan, Hai-Qiang Mai, Wai Tong Ng, et al.
The Lancet. Oncology|September 4, 2025
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
The Lancet. Oncology|September 4, 2025
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.
JAMA|March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical TrialYe-Lin Liang, Xu Liu, Liang-Fang Shen, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
Nature Communications|February 5, 2023
Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significanceMei Lin, Xiao-Long Zhang, Rui You, et al.
Cancer Cell|January 19, 2024
Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinomaXiao-Jing Du, Gao-Yuan Wang, Xiao-Dong Zhu, et al.
Lancet (London, England)|February 26, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialRui You, You-Ping Liu, Yu-Long Xie, et al.
Nature|March 12, 2026
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinomaJiawei Lv, Dan-Xue Zheng, Jin-Hui Liang, et al.
JAMA Oncology|October 10, 2024
Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging ClassificationJian-Ji Pan, Hai-Qiang Mai, Wai Tong Ng, et al.
The Lancet. Oncology|September 4, 2025
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
The Lancet. Oncology|September 4, 2025
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.
JAMA|March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical TrialYe-Lin Liang, Xu Liu, Liang-Fang Shen, et al.
Pageof 20